Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06237127 · ClinicalTrials.gov registry record · NA
Effects of Goji vs. Fiber on Macular Degeneration
A NA study of Age-related Macular Degeneration, sponsored by University of California, Davis.
- Recruiting
- Registry status
- NA
- Development phase
- 60
- Enrollment target
- 1
- Study location
NCT06237127: Recruiting NA study of Age-related Macular Degeneration, sponsored by University of California, Davis.
NCT06237127 is a NA study of Age-related Macular Degeneration that is actively recruiting participants, run by University of California, Davis. The registered enrollment target is 60 participants, below the 1,507-participant average among 74 other Age-related Macular Degeneration trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06237127, a NA study of Age-related Macular Degeneration, is actively recruiting participants, sponsored by University of California, Davis.
- RECRUITING
- Registry status
- NA
- Development phase
- 60 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this project is to conduct a clinical trial in 60 participants ranging from age 65-95 who are at risk for age-related macular degeneration (AMD). The study will evaluate the effects of 14g of goji berry intake or an equivalent amount and type of fiber, five days a week for six months, on visual health, gut microbiome profiles, skin carotenoid measures, and lipoprotein profiles.
Primary Outcome
MPOV provides an objective measure of macular pigments by using dual wavelength autofluorescence using the Heidelberg Spectralis to obtain HRA + OCT measures
Conditions Studied
Interventions
- DIETARY_SUPPLEMENT Goji berry
- DIETARY_SUPPLEMENT Fiber
Study Locations (1)
California
- UC Davis Eye Center, Tschannen Eye Institute - Sacramento
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2024-04-29 |
| Est. Completion | 2027-06-30 |
| Phase | NA |
What NCT06237127 shows while recruiting
NCT06237127 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 60 participants, a relatively small participant target, below the 1,507-participant average among 74 other Age-related Macular Degeneration trials with a reported enrollment target (96% lower).
The record links to 1 condition, with Age-related Macular Degeneration appearing as the primary indexed condition, and to 2 interventions - of which Goji berry is the first listed.
NCT06237127 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT06237127 about?
NCT06237127 is a clinical study titled "Effects of Goji vs. Fiber on Macular Degeneration". The goal of this project is to conduct a clinical trial in 60 participants ranging from age 65-95 who are at risk for age-related macular degeneration (AMD). The study will evaluate the effects of 14g of goji berry intake or an equivalent amount and type of fiber, five days a week for six months, on...
What is the current status of trial NCT06237127?
This trial is currently recruiting. It is a NA study. The enrollment target is 60 participants. The study started on 2024-04-29. Estimated completion is 2027-06-30.
What conditions does trial NCT06237127 study?
This clinical trial studies the following conditions: Age-related Macular Degeneration.
What interventions are being tested in trial NCT06237127?
The interventions under investigation include: Goji berry (DIETARY_SUPPLEMENT), Fiber (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT06237127?
This trial is sponsored by University of California, Davis, which has 657 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06237127 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Age-related Macular Degeneration
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06237127's enrollment target sits among peer trials
60 42nd of 74 higher than 31 of 74 other Age-related Macular Degeneration trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Age-related Macular Degeneration trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Village-Integrated Eye Worker Trial II
RECRUITING · NA
-
Visual Remapping to Aid Reading With Field Loss
RECRUITING · NA
-
Lutein, Zeaxathin, and Fish Oil Supplementation
RECRUITING · NA
-
Stem Cell Ophthalmology Treatment Study II
RECRUITING · NA
-
Multicenter Clinical Study of the SING-IMT in Patients with Late-stage AMD
RECRUITING · NA
-
AMD and Validation Rod-Meditated Dark Adaptation With Everyday Task Performance
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00576069 · 60 participants
Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma
- NCT01297400 · 60 participants · Phase 2
Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns
- NCT01734122 · 60 participants
Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor
- NCT01804634 · 60 participants · Phase 2
Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI